Coloplast

Coloplast's EBIT of 1,848 MDKK vs. the expected 2,018 MDKK points to a lower opening, as earnings stagnated at constant exchange rates, and estimates for 2026/27 need to come down. Free cash flow rose by 16% to DKK 6.3 billion, which covers an unchanged dividend of DKK 23 per share.

Coloplast exceeded expectations where it mattered: organic growth of 6% vs. the guided 5.6%, and sales of MDKK 7,355. DKK vs. MDKK 7,267. DKK. However, the operating profit disappointed at DKK 1,929 million. DKK, and the fish skin business Kerecis contracted again, so the share should open stable rather than strong.